Probiotics & Synbiotics CDMO Services

Probiotics & Synbiotics

Intro: Synbiotic Therapeutics

The convergence of microbiome science, synthetic biology, and biopharmaceutical innovation has created an entirely new therapeutic frontier: engineered probiotics and synbiotics. Unlike traditional probiotics—which rely on naturally occurring strains—engineered probiotics are purpose-designed microbial platforms with enhanced functionalities, from delivering therapeutic proteins in the gut to metabolizing harmful compounds. Synbiotics extend this further, pairing engineered microbes with prebiotics or tailored substrates that fuel specific activities, creating a self-reinforcing therapeutic ecosystem.

For innovators, the promise is profound: living medicines capable of addressing metabolic disorders, gastrointestinal diseases, immune dysfunction, and even cancer. But scaling these programs from bench to clinic requires specialized CDMO capabilities—bridging microbial fermentation expertise with GMP frameworks, regulatory fluency, and scalable bioprocess design.

Elise Biopharma provides this bridge. Headquartered in Québec, Elise Biopharma is an independent, science-driven CDMO specializing in precision microbial fermentation, recombinant biologics, next-generation food proteins, and now engineered probiotics & synbiotics. Our integrated pathway moves programs from DNA design through GMP release and worldwide logistics, ensuring your engineered probiotic or synbiotic product is developed with rigor, safety, and scalability in mind.

Why Engineered Probiotics & Synbiotics Need Specialized CDMOs

Traditional biologics CDMOs are optimized for monoclonal antibodies or recombinant proteins; traditional food fermentation facilities focus on GRAS organisms and enzyme production. Synbiotics fall in between—and beyond—requiring capabilities from both worlds.

Key complexities include:

1. Live Biotherapeutic Manufacturing (LBP): Regulatory agencies treat engineered probiotics differently from recombinant proteins. They must be manufactured under GMP, but also with controls for viability, stability, colonization potential, and biosafety.
2. Genetic Stability & Containment: Engineered strains often carry CRISPR edits, plasmids, or synthetic pathways. Maintaining genetic fidelity while preventing horizontal gene transfer is essential.
3. Combination Products (Probiotic + Prebiotic): Synbiotics must be developed with co-formulation science in mind—ensuring engineered microbes thrive alongside prebiotics, stabilizers, or delivery matrices.
4. Regulatory Pathways: Depending on indication, synbiotics may be regulated as biologics (IND/BLA), dietary supplements (GRAS/NDI), or hybrid products. Navigating this requires both FDA/EMA biologics expertise and food regulatory familiarity.
5. Scale-Up Challenges: While a lab may produce milligrams of engineered strains, clinical development requires 100L+ scale, and commercialization often means 1,000–10,000L GMP fermentors with reproducible growth, stability, and downstream workflows.

At Elise Biopharma, we’ve built an ecosystem that combines biopharma-grade GMP fermentation with food and nutraceutical know-how, allowing us to support programs whether they target IBD treatment under IND or functional supplements under GRAS.

Elise Biopharma’s Integrated Synbiotic CDMO Platform

1. Strain Engineering & Design Support

• CRISPR/Cas-based knockouts, knockins, and metabolic rewiring of probiotic strains (e.g., Lactobacillus, Bifidobacterium, E. coli Nissle, Saccharomyces boulardii).
• Plasmid optimization, codon tuning, and synthetic promoter libraries for stable expression of therapeutic proteins.
• Safety switches (kill-switches, auxotrophy engineering) to meet biosafety and regulatory expectations.
• In silico modeling of metabolic flux and host interaction (AI-driven strain optimization).

2. Upstream Process Development

• Fermentation expertise spanning aerobic/anaerobic systems with strict control of pH, redox balance, and nutrient availability.
• High-density fermentation strategies for maximizing CFU yield.
• Continuous culture and turbidostat systems for strains requiring long-term viability studies.
• Media design integrating prebiotic substrates to model synbiotic co-formulations during development.

3. Downstream Processing & Formulation

• Harvesting and stabilization workflows: centrifugation, microfiltration, spray drying, and lyophilization.
• Encapsulation technologies (alginate, lipid nanoparticles, polymer coatings) to ensure survival through gastric transit.
• Formulation compatibility testing with prebiotics, excipients, or co-therapeutics.
• Development of dosage forms: capsules, powders, liquid suspensions, topical creams, or combination devices.

4. Analytical & Quality Control

• Viability assays (CFU counts, flow cytometry, viability qPCR).
• Genetic stability testing: sequencing, plasmid retention, and integration site verification.
• Functional assays: protein secretion, metabolite production, host interaction models.
• Biosafety analytics: endotoxin testing, horizontal gene transfer risk assessments, antibiotic resistance gene profiling.
• PAT-driven monitoring during fermentation for real-time viability and metabolite profiling.

5. Regulatory & Compliance Support

• IND-enabling studies for engineered probiotics as live biotherapeutics.
• GRAS/NDI dossiers for synbiotic food and nutraceutical applications.
• Support for EU (EMA, EFSA), Canada (Health Canada), and Asia-Pacific regulatory frameworks.
• Environmental risk assessments and containment strategies.
• Preparation of CMC sections for clinical trial submissions.

6. Scale-Up & GMP Manufacturing

• Bioreactors ranging from 1L PD scale to 2,000L GMP working volume, with pathways to larger commercial partnerships (10,000L+).
• Single-use and stainless-steel systems designed for both aerobic and anaerobic organisms.
• Stringent environmental monitoring, contamination controls, and GMP batch record systems.
• Scalable lyophilization and spray-drying infrastructure for stable product release.

7. Global Logistics & Distribution

• Cold-chain logistics for live microbial products.
• Partnerships for shelf-stable formulations where cold chain is impractical.
• Distribution readiness across North America, EU, and Asia.

Why Elise Biopharma for Synbiotics?

• Dual DNA: We straddle biopharma and food biotech—rare among CDMOs. That means we can flex to your regulatory path, whether IND or GRAS.
• End-to-End Integration: From DNA design to GMP release, we eliminate handoffs that often derail engineered microbial programs.
• Regulatory Fluency: Our team understands FDA CBER expectations for live biotherapeutics as well as FDA CFSAN/EFSA expectations for food-grade probiotics.
• Customizable Capacity: Small-batch feasibility runs (1–10L) through pilot scale (100L–500L) to commercial volumes (2,000L+).
• Advanced Analytics: We treat probiotics with the rigor of biologics—PAT, omics-based QC, and genetic stability assays beyond the industry norm.
• Global Readiness: We build your program for multijurisdictional launch from day one.

Applications & Case Studies

1. Gut Health & IBD: Engineered E. coli Nissle expressing anti-inflammatory cytokines for Crohn’s.
2. Metabolic Disease: Synbiotic formulation of Lactobacillus engineered for bile acid metabolism + inulin prebiotic.
3. Oncology: Probiotics engineered to deliver immune checkpoint inhibitors directly to the tumor microenvironment.
4. Dermatology: Topical synbiotics combining Staphylococcus epidermidis strains with engineered pathways for antimicrobial peptide secretion.
5. Nutritional Supplements: Shelf-stable synbiotics for general wellness with GRAS-level safety.

Market Outlook & Strategic Value

The engineered probiotics and synbiotics market is projected to exceed $15B globally by 2030, with increasing cross-investment from biopharma, food tech, and venture capital. Pharma giants (e.g., Pfizer, Bayer, Nestlé Health Science) are entering the space through partnerships and acquisitions, validating its trajectory.

For innovators, the challenge is not demand—it’s execution: finding a CDMO that can bridge synthetic biology innovation with GMP manufacturing realities. Elise Biopharma is that bridge.

Let’s Partner for the Next Generation of Living Medicines!

Engineered probiotics and synbiotics are no longer limited to the wellness aisle—they are emerging as living medicines, functional foods, and precision therapies that address some of the most pressing health challenges of our time: inflammatory bowel disease, metabolic syndrome, oncology, and immune dysfunction. The scientific horizon is vast, but success requires the right translation partner.

At Elise Biopharma, we specialize in turning bold microbiome science into real-world therapeutic solutions. Our expertise spans the full arc of development: from CRISPR-edited probiotic strains to pilot-scale fermentation, from GRAS dossiers for consumer launch to IND-enabling CMC packages for FDA submission. This end-to-end integration means fewer handoffs, reduced regulatory risk, and faster time to market.

What sets Elise Biopharma apart is not just our technical excellence but our ability to strategically guide programs through both the biopharma and food biotech ecosystems. We understand that synbiotic programs often straddle dual markets, requiring careful balance between consumer-scale economics and pharma-grade compliance. Our infrastructure and expertise are built to support both.

If you are ready to take your engineered probiotic or synbiotic from concept to clinic—or from lab-scale prototype to global commercial launch—Elise Biopharma is your partner in shaping the future of microbiome therapeutics. Together, we can create not just products, but a new generation of living medicines that transform human health.

Learn more about our –> Gut Health CDMO Services

Email our team at info@elisebiopharma.com